Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

Susan W. Barnett, Brian Burke, Yide Sun, Elaine Kan, Harold Legg, Ying Lian, Kristen Bost, Fengmin Zhou, Amanda Goodsell, Jan Zur Megede, John Polo, John Donnelly, Jeffrey Ulmer, Gillis R. Otten, Chris J Miller, Michael Vajdy, Indresh K. Srivastava

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

We have previously shown that rhesus macaques were partially protected against high-dose intravenous challenge with simian-human immunodeficiency virus SHIVSF162P4 following sequential immunization with alphavirus replicon particles (VRP) of a chimeric recombinant VEE/SIN alphavirus (derived from Venezuelan equine encephalitis virus [VEE] and the Sindbis virus [SIN]) encoding human immunodeficiency virus type 1 HIV-1SF162 gp140ΔV2 envelope (Env) and trimeric Env protein in MF59 adjuvant (R. Xu, I. K. Srivastava, C. E. Greer, I. Zarkikh, Z. Kraft, L. Kuller, J. M. Polo, S. W. Barnett, and L. Stamatatos, AIDS Res. Hum. Retroviruses 22:1022-1030, 2006). The protection did not require T-cell immune responses directed toward simian immunodeficiency virus (SIV) Gag. We extend those findings here to demonstrate antibody-mediated protection against mucosal challenge in macaques using prime-boost regimens incorporating both intramuscular and mucosal routes of delivery. The macaques in the vaccination groups were primed with VRP and then boosted with Env protein in MF59 adjuvant, or they were given VRP intramuscular immunizations alone and then challenged with SHIVSF162P4 (intrarectal challenge). The results demonstrated that these vaccines were able to effectively protect the macaques to different degrees against subsequent mucosal SHIV challenge, but most noteworthy, all macaques that received the intramuscular VRP prime plus Env protein boost were completely protected. A statistically significant association was observed between the titer of virus neutralizing and binding antibodies as well as the avidity of anti-Env antibodies measured prechallenge and protection from infection. These results highlight the merit of the alphavirus replicon vector prime plus Env protein boost vaccine approach for the induction of protective antibody responses and are of particular relevance to advancing our understanding of the potential correlates of immune protection against HIV infection at a relevant mucosal portal of entry.

Original languageEnglish (US)
Pages (from-to)5975-5985
Number of pages11
JournalJournal of Virology
Volume84
Issue number12
DOIs
StatePublished - Jun 2010

Fingerprint

Alphavirus
replicon
Simian Immunodeficiency Virus
Replicon
Human immunodeficiency virus
Macaca
adjuvants
glycoproteins
Glycoproteins
Venezuelan Equine Encephalitis Viruses
Sindbis virus
Venezuelan equine encephalitis virus
HIV
Sindbis Virus
antibodies
Antibodies
Immunization
immunization
Proteins
Retroviridae

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. / Barnett, Susan W.; Burke, Brian; Sun, Yide; Kan, Elaine; Legg, Harold; Lian, Ying; Bost, Kristen; Zhou, Fengmin; Goodsell, Amanda; Zur Megede, Jan; Polo, John; Donnelly, John; Ulmer, Jeffrey; Otten, Gillis R.; Miller, Chris J; Vajdy, Michael; Srivastava, Indresh K.

In: Journal of Virology, Vol. 84, No. 12, 06.2010, p. 5975-5985.

Research output: Contribution to journalArticle

Barnett, SW, Burke, B, Sun, Y, Kan, E, Legg, H, Lian, Y, Bost, K, Zhou, F, Goodsell, A, Zur Megede, J, Polo, J, Donnelly, J, Ulmer, J, Otten, GR, Miller, CJ, Vajdy, M & Srivastava, IK 2010, 'Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant', Journal of Virology, vol. 84, no. 12, pp. 5975-5985. https://doi.org/10.1128/JVI.02533-09
Barnett, Susan W. ; Burke, Brian ; Sun, Yide ; Kan, Elaine ; Legg, Harold ; Lian, Ying ; Bost, Kristen ; Zhou, Fengmin ; Goodsell, Amanda ; Zur Megede, Jan ; Polo, John ; Donnelly, John ; Ulmer, Jeffrey ; Otten, Gillis R. ; Miller, Chris J ; Vajdy, Michael ; Srivastava, Indresh K. / Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. In: Journal of Virology. 2010 ; Vol. 84, No. 12. pp. 5975-5985.
@article{2abc3da0f98c4d658d4640d767f4ed14,
title = "Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant",
abstract = "We have previously shown that rhesus macaques were partially protected against high-dose intravenous challenge with simian-human immunodeficiency virus SHIVSF162P4 following sequential immunization with alphavirus replicon particles (VRP) of a chimeric recombinant VEE/SIN alphavirus (derived from Venezuelan equine encephalitis virus [VEE] and the Sindbis virus [SIN]) encoding human immunodeficiency virus type 1 HIV-1SF162 gp140ΔV2 envelope (Env) and trimeric Env protein in MF59 adjuvant (R. Xu, I. K. Srivastava, C. E. Greer, I. Zarkikh, Z. Kraft, L. Kuller, J. M. Polo, S. W. Barnett, and L. Stamatatos, AIDS Res. Hum. Retroviruses 22:1022-1030, 2006). The protection did not require T-cell immune responses directed toward simian immunodeficiency virus (SIV) Gag. We extend those findings here to demonstrate antibody-mediated protection against mucosal challenge in macaques using prime-boost regimens incorporating both intramuscular and mucosal routes of delivery. The macaques in the vaccination groups were primed with VRP and then boosted with Env protein in MF59 adjuvant, or they were given VRP intramuscular immunizations alone and then challenged with SHIVSF162P4 (intrarectal challenge). The results demonstrated that these vaccines were able to effectively protect the macaques to different degrees against subsequent mucosal SHIV challenge, but most noteworthy, all macaques that received the intramuscular VRP prime plus Env protein boost were completely protected. A statistically significant association was observed between the titer of virus neutralizing and binding antibodies as well as the avidity of anti-Env antibodies measured prechallenge and protection from infection. These results highlight the merit of the alphavirus replicon vector prime plus Env protein boost vaccine approach for the induction of protective antibody responses and are of particular relevance to advancing our understanding of the potential correlates of immune protection against HIV infection at a relevant mucosal portal of entry.",
author = "Barnett, {Susan W.} and Brian Burke and Yide Sun and Elaine Kan and Harold Legg and Ying Lian and Kristen Bost and Fengmin Zhou and Amanda Goodsell and {Zur Megede}, Jan and John Polo and John Donnelly and Jeffrey Ulmer and Otten, {Gillis R.} and Miller, {Chris J} and Michael Vajdy and Srivastava, {Indresh K.}",
year = "2010",
month = "6",
doi = "10.1128/JVI.02533-09",
language = "English (US)",
volume = "84",
pages = "5975--5985",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "12",

}

TY - JOUR

T1 - Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant

AU - Barnett, Susan W.

AU - Burke, Brian

AU - Sun, Yide

AU - Kan, Elaine

AU - Legg, Harold

AU - Lian, Ying

AU - Bost, Kristen

AU - Zhou, Fengmin

AU - Goodsell, Amanda

AU - Zur Megede, Jan

AU - Polo, John

AU - Donnelly, John

AU - Ulmer, Jeffrey

AU - Otten, Gillis R.

AU - Miller, Chris J

AU - Vajdy, Michael

AU - Srivastava, Indresh K.

PY - 2010/6

Y1 - 2010/6

N2 - We have previously shown that rhesus macaques were partially protected against high-dose intravenous challenge with simian-human immunodeficiency virus SHIVSF162P4 following sequential immunization with alphavirus replicon particles (VRP) of a chimeric recombinant VEE/SIN alphavirus (derived from Venezuelan equine encephalitis virus [VEE] and the Sindbis virus [SIN]) encoding human immunodeficiency virus type 1 HIV-1SF162 gp140ΔV2 envelope (Env) and trimeric Env protein in MF59 adjuvant (R. Xu, I. K. Srivastava, C. E. Greer, I. Zarkikh, Z. Kraft, L. Kuller, J. M. Polo, S. W. Barnett, and L. Stamatatos, AIDS Res. Hum. Retroviruses 22:1022-1030, 2006). The protection did not require T-cell immune responses directed toward simian immunodeficiency virus (SIV) Gag. We extend those findings here to demonstrate antibody-mediated protection against mucosal challenge in macaques using prime-boost regimens incorporating both intramuscular and mucosal routes of delivery. The macaques in the vaccination groups were primed with VRP and then boosted with Env protein in MF59 adjuvant, or they were given VRP intramuscular immunizations alone and then challenged with SHIVSF162P4 (intrarectal challenge). The results demonstrated that these vaccines were able to effectively protect the macaques to different degrees against subsequent mucosal SHIV challenge, but most noteworthy, all macaques that received the intramuscular VRP prime plus Env protein boost were completely protected. A statistically significant association was observed between the titer of virus neutralizing and binding antibodies as well as the avidity of anti-Env antibodies measured prechallenge and protection from infection. These results highlight the merit of the alphavirus replicon vector prime plus Env protein boost vaccine approach for the induction of protective antibody responses and are of particular relevance to advancing our understanding of the potential correlates of immune protection against HIV infection at a relevant mucosal portal of entry.

AB - We have previously shown that rhesus macaques were partially protected against high-dose intravenous challenge with simian-human immunodeficiency virus SHIVSF162P4 following sequential immunization with alphavirus replicon particles (VRP) of a chimeric recombinant VEE/SIN alphavirus (derived from Venezuelan equine encephalitis virus [VEE] and the Sindbis virus [SIN]) encoding human immunodeficiency virus type 1 HIV-1SF162 gp140ΔV2 envelope (Env) and trimeric Env protein in MF59 adjuvant (R. Xu, I. K. Srivastava, C. E. Greer, I. Zarkikh, Z. Kraft, L. Kuller, J. M. Polo, S. W. Barnett, and L. Stamatatos, AIDS Res. Hum. Retroviruses 22:1022-1030, 2006). The protection did not require T-cell immune responses directed toward simian immunodeficiency virus (SIV) Gag. We extend those findings here to demonstrate antibody-mediated protection against mucosal challenge in macaques using prime-boost regimens incorporating both intramuscular and mucosal routes of delivery. The macaques in the vaccination groups were primed with VRP and then boosted with Env protein in MF59 adjuvant, or they were given VRP intramuscular immunizations alone and then challenged with SHIVSF162P4 (intrarectal challenge). The results demonstrated that these vaccines were able to effectively protect the macaques to different degrees against subsequent mucosal SHIV challenge, but most noteworthy, all macaques that received the intramuscular VRP prime plus Env protein boost were completely protected. A statistically significant association was observed between the titer of virus neutralizing and binding antibodies as well as the avidity of anti-Env antibodies measured prechallenge and protection from infection. These results highlight the merit of the alphavirus replicon vector prime plus Env protein boost vaccine approach for the induction of protective antibody responses and are of particular relevance to advancing our understanding of the potential correlates of immune protection against HIV infection at a relevant mucosal portal of entry.

UR - http://www.scopus.com/inward/record.url?scp=77952688015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952688015&partnerID=8YFLogxK

U2 - 10.1128/JVI.02533-09

DO - 10.1128/JVI.02533-09

M3 - Article

VL - 84

SP - 5975

EP - 5985

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 12

ER -